Whole Genome Approaches to Complex Kidney Disease
- What are the technologies that will be most useful for human genetics over the next 3-5 years?
- What populations, clinical samples, and phenotypic information do we need to most effectively identify susceptibility genes for complex glomerular diseases?
- How can we best use existing repositories and databases to extract information about kidney disease?
- How can we analyze, interpret and share the massive datasets that will be generated by whole genome/exome approaches?
- What are the relevant ethical, legal, and social issues now and what is on the horizon?
- How can we enhance public access to genetic information and help individuals understand the concept of genetic susceptibility in general and their own genetic profiles in particular?
- Which professionals will counsel individuals about their genetic risk for kidney disease, and what resources and training do they need?
- How might genetic susceptibility information be integrated into nephrology and primary care practice to improve patient outcomes and reduce the burden of chronic kidney disease?
Barry Freedman, Wake Forest Baptist Medical Center
Linda Kao, Johns Hopkins Bloomberg School of Public Health
Matthias Kretzler, University of Michigan
Martin Pollak, Harvard University
John Sedor, Case Western Reserve University
Andrey Shaw, Washington University in St. Louis - Co-Chair
Jeffrey Kopp, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Co-Chair
Michael Flessner, NIDDK
Paul Kimmel, NIDDK
Rebekah Rasooly, NIDDK
Sara Hull, National Human Genome Research Institute - Co-Chair
Cheryl Winkler, National Cancer Institute